We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+1.14%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$610M
AUM Growth
+$126M
Cap. Flow
+$157M
Cap. Flow %
25.76%
Top 10 Hldgs %
65.04%
Holding
54
New
16
Increased
19
Reduced
10
Closed
8

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$46.8M
2
WGS icon
GeneDx Holdings
WGS
+$42.7M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$20M
4
ALKS icon
Alkermes
ALKS
+$15.9M
5
PRCT icon
Procept Biorobotics
PRCT
+$15.9M

Top Sells

Rank Stock Value
1
ICLR icon
Icon
ICLR
+$20M
2
FOLD
Amicus Therapeutics
FOLD
+$16.4M
3
SEM
Select Medical
SEM
+$15.4M
4
ROIV icon
Roivant Sciences
ROIV
+$11.5M
5
AVTR icon
Avantor
AVTR
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.84%
2 Industrials 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KIDS icon
26
OrthoPediatrics
KIDS
$617M
$4.8M 0.79%
302,399
+165,658
+121% +$2.89M
IMVT icon
27
Immunovant
IMVT
$8.51B
$4.37M 0.72%
175,825
-67,579
-28% -$1.75M
ICUI icon
28
ICU Medical
ICUI
$4.38B
$3.55M 0.58%
+27,450
New +$3.95M
TECX
29
Tectonic Therapeutic
TECX
$696M
$2.47M 0.4%
79,872
-155,128
-66% -$3.82M
RCKT icon
30
Rocket Pharmaceuticals
RCKT
$424M
$2.45M 0.4%
683,856
-60,086
-8% -$239K
UPB
31
Upstream Bio Inc
UPB
$366M
$2.17M 0.36%
+241,123
New +$4.34M
PLRX icon
32
Pliant Therapeutics
PLRX
$68.7M
$2.1M 0.34%
1,667,600
+111,856
+7% +$141K
OMER icon
33
Omeros
OMER
$1.35B
$1.85M 0.3%
+174,800
New +$2.06M
ISRG icon
34
Intuitive Surgical
ISRG
$132B
$1.84M 0.3%
+4,000
New +$2.02M
ANTX icon
35
AN2 Therapeutics
ANTX
$211M
$1.76M 0.29%
+515,754
New +$1.06M
ACET icon
36
Adicet Bio
ACET
$84.8M
$1.7M 0.28%
250,244
– –
RGNX icon
37
Regenxbio
RGNX
$638M
$1.68M 0.27%
+200,000
New +$2.1M
COYA icon
38
Coya Therapeutics
COYA
$108M
$1.66M 0.27%
+420,360
New +$1.97M
VKTX icon
39
Viking Therapeutics
VKTX
$3.75B
$1.46M 0.24%
+45,000
New +$1.45M
IRTC icon
40
iRhythm Holdings
IRTC
$3.96B
$1.18M 0.19%
+10,000
New +$1.44M
TBI
41
Trueblue
TBI
$326M
$974K 0.16%
249,107
-193,447
-44% -$859K
IMRX icon
42
Immuneering
IMRX
$323M
$650K 0.11%
+123,409
New +$633K
PVLA
43
Palvella Therapeutics
PVLA
$2.16B
$623K 0.1%
+5,000
New +$522K
NVCR icon
44
NovoCure
NVCR
$2.08B
$549K 0.09%
+50,400
New +$629K
RNTX
45
Rein Therapeutics
RNTX
$65.7M
$535K 0.09%
411,600
-31,000
-7% -$38.5K
TMDX icon
46
Transmedics
TMDX
$3.07B
$497K 0.08%
+5,000
New +$652K
AVTR icon
47
Avantor
AVTR
$9.86B
– –
-898,499
Closed -$10.3M
BBIO icon
48
BridgeBio Pharma
BBIO
$15B
– –
-30,000
Closed -$2.29M
CDNA icon
49
CareDx
CDNA
$2.58B
– –
-250,000
Closed -$4.71M
FOLD
50
DELISTED
Amicus Therapeutics
FOLD
– –
-1,150,000
Closed -$16.4M
1
2
3

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q1 2026 Portfolio in Review

As of Q1 2026, Prosight Management held 54 positions worth $610M, up 26% from $484M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Prosight Management deployed $157M of net new capital in Q1 2026, opening 16 new positions and adding to 19 existing holdings. Its largest new stake was Alkermes: 513,632 shares worth $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Roivant Sciences, an estimated $11.5M trimmed.

  • Prosight Management's largest Q1 2026 buy was Alkermes: 513,632 shares worth $18.2M.
  • Prosight Management added most to Boston Scientific in Q1 2026, an estimated $46.8M increase.
  • Prosight Management's biggest Q1 2026 reduction was Roivant Sciences, cutting an estimated $11.5M.
  • Prosight Management fully exited Icon in Q1 2026, selling an estimated $20M.
  • Prosight Management's ten largest holdings make up 65% of its $610M portfolio in Q1 2026.
  • Prosight Management opened 16 new positions and closed 8 in Q1 2026.
  • Prosight Management's portfolio value rose 26% quarter-over-quarter to $610M.

Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.